0.1.0 - ci-build

oncologyfhirigkenya - Local Development build (v0.1.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

: Tumor Markers - XML Representation

Active as of 2025-06-24

Raw xml | Download


<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="tumor-markers"/>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: CodeSystem tumor-markers</b></p><a name="tumor-markers"> </a><a name="hctumor-markers"> </a><p>This case-sensitive code system <code>http://example.org/fhir/CodeSystem/tumor-markers</code> defines the following codes:</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style="white-space:nowrap">CEA<a name="tumor-markers-CEA"> </a></td><td>Carcinoembryonic Antigen</td></tr><tr><td style="white-space:nowrap">AFP<a name="tumor-markers-AFP"> </a></td><td>Alpha-fetoprotein</td></tr><tr><td style="white-space:nowrap">PSA<a name="tumor-markers-PSA"> </a></td><td>Prostate-Specific Antigen</td></tr><tr><td style="white-space:nowrap">CA125<a name="tumor-markers-CA125"> </a></td><td>Cancer Antigen 125</td></tr><tr><td style="white-space:nowrap">CA15_3<a name="tumor-markers-CA15_3"> </a></td><td>Cancer Antigen 15-3</td></tr><tr><td style="white-space:nowrap">CA19_9<a name="tumor-markers-CA19_9"> </a></td><td>Cancer Antigen 19-9</td></tr><tr><td style="white-space:nowrap">LDH<a name="tumor-markers-LDH"> </a></td><td>Lactate Dehydrogenase</td></tr><tr><td style="white-space:nowrap">hCG<a name="tumor-markers-hCG"> </a></td><td>Human Chorionic Gonadotropin</td></tr><tr><td style="white-space:nowrap">B2M<a name="tumor-markers-B2M"> </a></td><td>Beta-2 Microglobulin</td></tr></table></div>
  </text>
  <url value="http://example.org/fhir/CodeSystem/tumor-markers"/>
  <version value="0.1.0"/>
  <name value="TumorMarkers"/>
  <title value="Tumor Markers"/>
  <status value="active"/>
  <experimental value="false"/>
  <date value="2025-06-24T09:16:08+00:00"/>
  <publisher value="Medby_Tech"/>
  <contact>
    <name value="Medby_Tech"/>
    <telecom>
      <system value="url"/>
      <value value="http://example.org/example-publisher"/>
    </telecom>
  </contact>
  <description
               value="Tumor markers commonly used in oncology diagnostics and monitoring in Kenya."/>
  <caseSensitive value="true"/>
  <content value="complete"/>
  <count value="9"/>
  <concept>
    <code value="CEA"/>
    <display value="Carcinoembryonic Antigen"/>
  </concept>
  <concept>
    <code value="AFP"/>
    <display value="Alpha-fetoprotein"/>
  </concept>
  <concept>
    <code value="PSA"/>
    <display value="Prostate-Specific Antigen"/>
  </concept>
  <concept>
    <code value="CA125"/>
    <display value="Cancer Antigen 125"/>
  </concept>
  <concept>
    <code value="CA15_3"/>
    <display value="Cancer Antigen 15-3"/>
  </concept>
  <concept>
    <code value="CA19_9"/>
    <display value="Cancer Antigen 19-9"/>
  </concept>
  <concept>
    <code value="LDH"/>
    <display value="Lactate Dehydrogenase"/>
  </concept>
  <concept>
    <code value="hCG"/>
    <display value="Human Chorionic Gonadotropin"/>
  </concept>
  <concept>
    <code value="B2M"/>
    <display value="Beta-2 Microglobulin"/>
  </concept>
</CodeSystem>